PMID- 8631014
OWN - NLM
STAT- MEDLINE
DCOM- 19960703
LR  - 20220316
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 56
IP  - 4
DP  - 1996 Feb 15
TI  - Retrospective study of the correlation between the DNA repair protein 
      alkyltransferase and survival of brain tumor patients treated with carmustine.
PG  - 783-8
AB  - We tested the hypothesis that the level of the DNA repair protein 
      O6-alkylguanine-DNA alkyltransferase in brain tumors was correlated with 
      resistance to carmustine (BCNU) chemotherapy. Alkyltransferase levels in 
      individual cells in sections from 167 primary brain tumors treated with BCNU were 
      quantitated with an immunofluorescence assay using monoclonal antibodies against 
      human alkyltransferase. Patients with high levels of alkyltransferase had shorter 
      time to treatment failure (P = 0.05) and death (P = 0.004) and a death rate 1.7 
      times greater than patients with low alkyltransferase levels. Furthermore, the 
      size of the subpopulation of cells with high levels of alkyltransferase was 
      correlated directly with drug resistance. For all tumors the variables most 
      closely correlated with survival, in order of importance, were age, tumor grade, 
      and alkyltransferase levels. For glioblastoma multiforme, survival was more 
      strongly correlated with alkyltransferase levels than with age. These results 
      should encourage prospective studies to evaluate alkyltransferase levels as a 
      method, for identifying brain tumor patients with the best likelihood of response 
      to BCNU chemotherapy.
FAU - Belanich, M
AU  - Belanich M
AD  - Applied Genetics Inc., Freeport, New York 11520, USA.
FAU - Pastor, M
AU  - Pastor M
FAU - Randall, T
AU  - Randall T
FAU - Guerra, D
AU  - Guerra D
FAU - Kibitel, J
AU  - Kibitel J
FAU - Alas, L
AU  - Alas L
FAU - Li, B
AU  - Li B
FAU - Citron, M
AU  - Citron M
FAU - Wasserman, P
AU  - Wasserman P
FAU - White, A
AU  - White A
FAU - Eyre, H
AU  - Eyre H
FAU - Jaeckle, K
AU  - Jaeckle K
FAU - Schulman, S
AU  - Schulman S
FAU - Rector, D
AU  - Rector D
FAU - Prados, M
AU  - Prados M
FAU - Coons, S
AU  - Coons S
FAU - Shapiro, W
AU  - Shapiro W
FAU - Yarosh, D
AU  - Yarosh D
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - EC 2.1.1.- (Methyltransferases)
RN  - EC 2.1.1.63 (O(6)-Methylguanine-DNA Methyltransferase)
RN  - U68WG3173Y (Carmustine)
SB  - IM
MH  - Antibodies, Monoclonal
MH  - Antineoplastic Agents, Alkylating/*therapeutic use
MH  - Brain Neoplasms/*drug therapy/mortality/*pathology/radiotherapy
MH  - Carmustine/*therapeutic use
MH  - Combined Modality Therapy
MH  - *DNA Repair
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Methyltransferases/*analysis
MH  - Middle Aged
MH  - O(6)-Methylguanine-DNA Methyltransferase
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Time Factors
EDAT- 1996/02/15 00:00
MHDA- 1996/02/15 00:01
CRDT- 1996/02/15 00:00
PHST- 1996/02/15 00:00 [pubmed]
PHST- 1996/02/15 00:01 [medline]
PHST- 1996/02/15 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1996 Feb 15;56(4):783-8.